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a  b  s  t  r  a  c  t
Objectives:  The  coverage  policies  of many  commercial  insurers  in  the  United  States  do  not  include  coverage
of stereotactic  radiosurgery  (SRS) for  intractable  epilepsy  despite  recent  Level  I evidence  supporting
its  efficacy.  We  sought  to assess  the  efficacy  of an evidence-based  methodology  in  obtaining  coverage
approval  of  SRS  for  intractable  epilepsy.
Patients  and Methods:  The  clinical  policy  guidelines  from  five  of  the  largest  United  States  commercial
insurers  were  reviewed  for  their  language  regarding  coverage  of  SRS  for epilepsy.  An evidence-based
questionnaire  was  created  for  temporal  lobe  epilepsy  and  extratemporal  lobe  epilepsy  based  on  recent
evidence.  Telephone  interviewers  of  Insurers  assessed  the  likelihood  of SRS coverage  for  an  epilepsy
patient  meeting  the  clinical  inclusion  criteria in the  questionnaire.  This  likelihood  was  assessed  numer-
ically  based  on  interviewee  response  (2 =  yes,  1  =  dependent  on peer-to-peer,  0  =  no).
Results:  Of  the  five  policy  guidelines,  none  included  literature  more  recent  than  2017.  For  TLE,  3/5  insur-
ance  companies  indicated  likely  SRS  coverage;  2/5  indicated  peer-to-peer  discussion  dependence  for
patients  meeting  questionnaire  criteria  for a score  of 8/10.  For  extratemporal  TLE,  2/5  companies  indi-
cated  likely  SRS coverage  and  3/5  indicated  peer-to-peer  discussion  dependence  for  a total  score  of
7/10.
Conclusion:  Creation  of  an evidence-based  methodology  in approaching  commercial  insurers  greatly
increased  the  likelihood  of SRS  coverage  for an  indication  (intractable  epilepsy)  widely  perceived  as
investigational.  These  results  should  pave  the  way  for epilepsy  patients  to  receive  coverage  should  they
be appropriate  SRS  candidates.
© 2020  Greater  Poland  Cancer  Centre.  Published  by  Elsevier  B.V.  All  rights  reserved.. Introduction
For nearly two decades, Level I evidence has demonstrated that
or patients with temporal lobe epilepsy refractory to at least two
ntiepileptic drug trials, the likelihood of seizure freedom with con-
inued medical therapy alone is less than 10%.1 The randomized
ontrolled trial by Wiebe et al. in 2001 established that anterior
emporal lobectomy provided markedly superior one-year seizure
reedom of 58% compared to 8% with continued medical manage-
ent alone.1 More recent nationwide analysis of anterior temporal
obectomy has demonstrated this operative procedure to produce
ow morbidity.2
However, for patients who either are not surgical candidates,
r prefer noninvasive intervention, stereotactic radiosurgery (SRS)
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507-1367/© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reshas emerged as a potential alternative for the treatment of
intractable temporal lobe epilepsy (TLE), spurred initially by the
success of SRS in treating epilepsy associated with cerebral arte-
riovenous malformations.3 This resulted in pilot attempts at SRS
in treating TLE utilizing a dose of 20 Gy; unfortunately, this dose
remained inadequate to control TLE, with the persistent seizures
resulting in fatal consequences.4 In part due to this inadequate
control, the SRS dose of 24 Gy was used for the Radiosurgery versus
Open Surgery for mesial temporal lobe Epilepsy (ROSE) randomized
multicenter clinical trial, resulting in a three-year seizure freedom
(Engel Class I) rate of 52%.5 While this rate failed to prove the
noninferiority of SRS compared with anterior temporal lobectomy
(78% three-year seizure freedom rate), for TLE patients who  are
not surgical candidates, SRS represents a treatment modality with
proven seizure control superior to continued medical management
alone.1,5,6
Unfortunately, despite the inclusion of intractable epilepsy as
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tion Oncology (ASTRO) published model policies, recent work has
ndicated that the coverage policies of the largest publicly available
ommercial insurers in the United States do not include routine
overage of SRS for intractable epilepsy.7 We  sought to assess the
fficacy of an evidence-based methodology in obtaining coverage
pproval of SRS for intractable epilepsy.
. Materials and methods
The clinical policy guidelines from five of the largest publicly
vailable commercial insurers in the United States (Aetna, Anthem,
igna, Humana, United) were reviewed for their language regarding
overage of SRS for epilepsy. An evidence-based questionnaire was
reated from the ROSE trial inclusion criteria for TLE patients, and
ased on recent epilepsy surgery cohort studies for extratemporal
pilepsy patients (Table 1). Insurers were subsequently contacted
y telephone within the same month of policy guideline review and
uestionnaire creation (October 2019); radiation oncology medical
irectors were interviewed to assess the likelihood of SRS cover-
ge for an epilepsy patient meeting the clinical inclusion criteria in
he questionnaire. For TLE, criteria included: 1. Sufficient continu-
us video electroencephalography to determine a unilateral medial
emporal seizure focus with MRI-concordant hippocampal sclero-
is, 2. Wada test/functional MRI  to lateralize language, 3. Minimum
f three focal-onset seizures with impairment of consciousness
ver a three month period despite at least two antiepileptic med-
cation trials, 4. Absence of neurologic deficits or visual deficits
utside of seizure episodes, 5. Absence of psychiatric diagnoses, 6.
eemed a nonoperative candidate by a neurosurgeon (Table 1). For
xtratemporal epilepsy, criteria included: 1. Diagnosis of epilepsy
stablished by a neurologist, 2. Persistent epilepsy despite more
han one antiepileptic drug trial, 3. Proposed anatomic region to be
argeted aligning with anatomy associated with seizure reduction
able 1
uestionnaire used during assessment of insurance coverage for stereotactic radiosurgery
n  optimal candidate and should never be denied SRS coverage.
Temporal Lobe Epilepsy 
1. Has the patient had sufficient continuous video electroencephalography to determin
2.  Does the patient have magnetic resonance imaging (MRI) evidence of concordant u
secondary cortical lesions?
3. Has the patient had a Wada test or a functional MRI  to lateralize language?
4.  Has the patient completed a standard battery of neuropsychological testing?
5. Has the patient had at least 3 focal-onset seizures with impairment of consciousne
antiepileptic medication trials?
6.  Has the patient had exclusion of supratentorial abnormalities by brain MRI?
7.  Does the patient have absence of neurological deficits outside of seizure episodes?
8.  Does the patient have absence of visual deficits outside of seizure episodes?
9.  Does the patient have absence of psychiatric diagnoses?
10. If the patient has never had anterior temporal lobectomy, has the patient been de
anterior temporal lobectomy?
Extratemporal Epilepsy 
1.  Does the patient have a diagnosis of epilepsy established by a Neurologist?
2.  Has the patient’s epilepsy persisted despite persisted despite more than one antiep
3.  Does the proposed anatomic region to be targeted align with anatomy associated w
evidence-based literature?
4. Is there imaging evidence (i.e. MRI) of the anatomic region to be targeted correlatin
5.  Has the patient been deemed an appropriate candidate for stereotactic radiosurgercology and Radiotherapy 25 (2020) 899–901
in evidence-based literature, 4. Deemed an appropriate SRS can-
didate by radiation oncology and neurosurgery (Table 1). A score
was derived to assess the likelihood of SRS coverage for TLE and
extratemporal TLE based on interviewee response (2 = yes, 1 =
dependent on individual MD discussion during peer-to-peer, 0 =
no).
3. Results
Of the five policy guidelines, none had included the results of the
ROSE trial despite it having been published more than 18 months
prior to review. As a result, two deemed SRS for intractable epilepsy
listed as investigational due to “insufficient evidence”, one failed to
mention epilepsy as an indication for SRS, one cited a policy of all
SRS epilepsy cases requiring medical review, and the fifth cited the
lack of Level I evidence precluding the formation of guidelines. No
guideline cited literature more recent than 2017.
For TLE, three of five insurance companies indicated SRS cov-
erage was likely for patients meeting the questionnaire criteria,
with the other two  expressing coverage dependent on peer-to-
peer discussion for a total score of 8/10. For extratemporal TLE,
two insurance companies indicated likely SRS coverage with the
remaining three recommending coverage dependent on peer-to-
peer discussion for a total score of 7/10.
4. Discussion
The results from this study indicate the benefits of pursuing an
evidence-based methodology in approaching insurance carriers,
particularly in the instance of newer Level 1 evidentiary studies,
which in this instance was  universally excluded from the insurer
policy guidelines. The positive response to questions derived from
the ROSE study reaffirm the benefits of remaining up-to-date with
 (SRS) treatment of intractable epilepsy; any patient meeting all of these criteria is
Yes/No
e a unilateral medial temporal seizure focus?
nilateral hippocampal sclerosis without significant
ss over a 3 month period despite two or more
emed by Neurosurgery as a nonoperative candidate for
Yes/No
ileptic drug trial?
ith seizure reduction following focal treatment in
g with the diagnosis of epilepsy?
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ractice-changing literature in advocating for optimal care for our
atients. The results for extratemporal epilepsy coverage, inspired
y recent anatomically-based studies indicating the piriform cor-
ex as a potential anatomic target for surgical or SRS treatment of
ntractable epilepsy,8,9 indicate the potential for hypothesis-driven
RS treatment of intractable epilepsy beyond the boundaries of the
OSE trial to be covered by insurance under appropriate conditions.
imitations to this study include its reliance on theoretical exam-
les as opposed to actual patient cases, and the interview-based
ature of the methodology.
In conclusion, creation of an evidence-based methodology in
pproaching commercial insurers greatly increased the likelihood
f SRS coverage for an indication (intractable epilepsy) widely per-
eived as investigational. For TLE patients who  are nonoperative
andidates, the three-year seizure freedom rate of 52% provided
y SRS in the ROSE trial far exceeds the 8% seizure freedom rate
f continued medical management alone,1,5 indicating that these
atients should almost never be denied coverage of SRS in treat-
ent of their intractable epilepsy. These results should provide a
ramework for these patients to receive coverage should they be
ppropriate candidates for SRS.
tatement of author contributions
Conception and design: McClelland; Data collection: McClel-
and, Verma; Data interpretation: McClelland, Verma; Manuscript
riting: McClelland; Final approval of manuscript: McClelland,
erma.onflict of interest




Dr. McClelland receives research funding from the Indianapolis
Public Transportation Corporation. The authors would like to thank
Jordan Wheatley for invaluable assistance.
References
1. Wiebe S, Blume WT,  Girvin JP, et al. A randomized, controlled trial of surgery for
temporal-lobe epilepsy. N Engl J Med. 2001;345:311–318.
2. McClelland 3rd S, Guo H, Okuyemi KS. Population-based analysis of morbidity
and  mortality following surgery for intractable temporal lobe epilepsy in the
United States. Arch Neurol. 2011;68:725–729.
3. Kurita H, Kawamoto S, Suziki I, et al. Control of epilepsy associated with cerebral
arteriovenous malformations after radiosurgery. J Neurol Neurosurg Psychiatry.
1998;65:648–655.
4. Srikijvilaikul T, Najm I, Foldvary-Schaefer N, et al. Failure of gamma  knife radio-
surgery for mesial temporal lobe epilepsy: Report of five cases. Neurosurgery.
2004;54:1395–1404.
5. Barbaro NM,  Quigg M,  Ward MM,  et al. Radiosurgery versus open surgery for
mesial temporal lobe epilepsy: The randomized, controlled ROSE trial. Epilepsia.
2018;59:1198–1207.
6. McClelland 3rd S, Jaboin JJ. Optimal treatment for African-Americans with
intractable mesial temporal lobe epilepsy remains anterior temporal lobectomy.
Clin Neurol Neurosurg.  2018;174:247.
7. Verma V, Ludmir EB, Mesko SM, et al. Commercial insurance coverage of
advanced radiation therapy techniques compared with American Society for
Radiation Oncology model policies. Pract Radiat Oncol. 2019, pii: S1879-
8500(19)30251-30256. doi:10.1016/j.prro.2019.08.005. [Epub ahead of print].8. Galovic M, Baudracco I, Wright-Goff E, et al. Association of piriform cortex
resection with surgical outcomes in patients with temporal lobe epilepsy. JAMA
Neurol.  2019;76:690–700.
9. McClelland 3rd S, Watson GA. Development of a standardized method for radia-
tion therapy contouring of the piriform cortex. J Radiosurg SBRT. 2019;6, 247-149.
